On this page you will find information for pharmacists involved in the RECOVERY Trial, including FAQs and HRA Pharmacy Assurance.
February 2024: RECOVERY trial sotrovimab has received a further expiry date extension, to 48 months. Note the the sotrovimab comparison is due to close on 31 March 2024, so this only affects sites holding batch 2T8F (which had a previous expiry date of 29 Februrary 2024).
July 2023: RECOVERY trial sotrovimab has received a further expiry date extension, to 36 months. This will require relabelling existing stock. Please see sotrovimab 36 month expiry documents below.
June 2023: Following the closing of the molnupiravir and Paxlovid arms, sites should return any unused study drug to the site pharmacy for general use, following their local guidelines.
RECOVERY Trial pharmacy briefing document and FAQs (This version was updated to reflect 48 month sotrovimab expiry extension)
Sotrovimab expiry date extension